AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32651298 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 27395
Study 32651298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 27395
Study 32651298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 27395
Study 32651298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral factor Xa inhibitors (combined analysis)
Number of subjects: 27395
Study 32651298 — intervention group
Group type: COMPARATOR
Intervention: Additional randomized controlled trials (16,177 participants)
Number of subjects: 27395
Study 36379323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 1093
Study 33385624 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose protocol (120 kV, 100 mA)
Number of subjects: 76
Study 33385624 — intervention group
Group type: COMPARATOR
Intervention: Ultra-low-dose protocol (80 kV, 10 mA)
Number of subjects: 76
Study 32856058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified oocytes
Number of subjects: 1844
Study 32856058 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 1844
Study 32856058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified oocytes with efficiency taken into account
Number of subjects: 1844
Study 32856058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified oocytes with 100% post-warming survival
Number of subjects: 1844
Study 32856058 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes with 100% post-warming survival
Number of subjects: 1844
Study 33611671 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ultra-low-dose prednisolone
Number of subjects: 0
Study 33611671 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose prednisolone for a week during acute viral infection
Number of subjects: 0
Study 33611671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of corticosteroids for treating relapses
Number of subjects: 0
Study 32976954 — intervention group
Group type: EXPERIMENTAL
Intervention: fPIP (4-session psychodynamic-based focused parent-infant psychotherapy)
Number of subjects: 154
Study 32976954 — intervention group
Group type: COMPARATOR
Intervention: TAU (standard pediatric care)
Number of subjects: 154
Study 35605678 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar (4 mg)
Number of subjects: 82
Study 35605678 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (160 mg)
Number of subjects: 82
Study 33045334 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen every 6 hours for pain, with 5 mg/325 mg oxycodone-acetaminophen for breakthrough pain
Number of subjects: 80
Study 33045334 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/325 mg oxycodone-acetaminophen prescribed as 1 to 2 tablets every 6 hours as needed for pain (standard of care)
Number of subjects: 80
Study 32369570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical mechanical debridement with adjunct low-level laser therapy (LLLT)
Number of subjects: 67
Study 32369570 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical mechanical debridement alone
Number of subjects: 67
Study 34144529 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera (Ashwagandha) 6 gm in powder form or extracts in tablets, or 500-1000 mg capsule for 8-12 weeks
Number of subjects: 77
Study 34144529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 33257489 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Number of subjects: 420
Study 33257489 — intervention group
Group type: COMPARATOR
Intervention: No NSAIDs (control group)
Number of subjects: 420
Study 35766272 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of baseline and 1-year BNP concentration
Number of subjects: 6740
Study 35766272 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of average BNP concentration
Number of subjects: 6740
Study 35766272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality rate
Number of subjects: 6740
Study 32228146 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised screening sites added in low-income neighbourhoods
Number of subjects: 0
Study 32228146 — intervention group
Group type: COMPARATOR
Intervention: Screening invitation
Number of subjects: 0
Study 32816872 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive sprint interval training (SIT) (4‐6×30 s at maximum effort)
Number of subjects: 54
Study 32816872 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐intensity continuous training (MICT) (40‐60 min at 60% of maximal aerobic capacity (VO 2peak))
Number of subjects: 54
Study 33233972 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised word finding therapy plus usual care
Number of subjects: 278
Study 33233972 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 278
Study 33233972 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus attention control
Number of subjects: 278
Study 35483248 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referent task (n = 230)
Number of subjects: 450
Study 35483248 — intervention group
Group type: COMPARATOR
Intervention: Other-referent task (n = 220)
Number of subjects: 450
Study 32880909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1027
Study 32880909 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab
Number of subjects: 1027
Study 34668068 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided local anesthetic infiltration technique (LDAI)
Number of subjects: 62
Study 34668068 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block (US-TAP)
Number of subjects: 62
Study 35332504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-yoga training
Number of subjects: 32
Study 35332504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 34247896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-dose intensity-modulated radiotherapy and ADT (6 months)
Number of subjects: 67
Study 33878855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zinc and arginine (lotion A)
Number of subjects: 40
Study 33878855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lotion B)
Number of subjects: 40
Study 35211189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 65
Study 35211189 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 65
Study 33645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 79
Study 33645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 79
Study 33645313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 33645313 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 79
Study 32406924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 8647
Study 32406924 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic signature
Number of subjects: 8647
Study 32406924 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic signature adjusted for MEDAS scores
Number of subjects: 8647
Study 32406924 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically inferred metabolic signature
Number of subjects: 8647
Study 34341321 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced video education session
Number of subjects: 120
Study 34341321 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 120
Study 33136654 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal isometric exercise intervention (MIET); 3 sessions per week of 4, 2-min isometric contractions with 1-min rest for 6 weeks.
Number of subjects: 20
Study 33136654 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON); no specific intervention details provided.
Number of subjects: 20
Study 33095777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative home-based exercise therapy with one exercise
Number of subjects: 0
Study 33650634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol (FM)
Number of subjects: 250
Study 33650634 — intervention group
Group type: COMPARATOR
Intervention: IV iron (IV FCM)
Number of subjects: 250
Study 32553767 — intervention group
Group type: EXPERIMENTAL
Intervention: Operations performed at the highest volume centers
Number of subjects: 22739
Study 32553767 — intervention group
Group type: COMPARATOR
Intervention: Operations performed at the lowest volume hospitals
Number of subjects: 22739
Study 32553767 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 22739
Study 36167555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-pseudomonal antibiotic treatment with intravenous beta-lactam and oral ciprofloxacin for 14 days
Number of subjects: 150
Study 36167555 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 150
Study 34633418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) therapy
Number of subjects: 172
Study 34633418 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (continuous subcutaneous insulin infusion or multiple daily insulin injections with or without CGM)
Number of subjects: 172
Study 33152805 — intervention group
Group type: EXPERIMENTAL
Intervention: mental illness anti-stigma curriculum
Number of subjects: 751
Study 33152805 — intervention group
Group type: EXPERIMENTAL
Intervention: contact with 2 young adults with mental illness
Number of subjects: 751
Study 33152805 — intervention group
Group type: COMPARATOR
Intervention: merged control (printed materials/no intervention)
Number of subjects: 751
Study 33328035 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Patient Management (RPM) intervention
Number of subjects: 1538
Study 33328035 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1538
Study 33328035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from RPM group
Number of subjects: 1538
Study 33328035 — intervention group
Group type: COMPARATOR
Intervention: Combined data from UC group
Number of subjects: 1538
Study 33112655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI breakfast (GI=71)
Number of subjects: 10
Study 33112655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI breakfast (GI=40)
Number of subjects: 10
Study 33112655 — intervention group
Group type: COMPARATOR
Intervention: Breakfast omission
Number of subjects: 10
Study 35446292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster nursing
Number of subjects: 0
Study 35446292 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 0
Study 32935564 — intervention group
Group type: COMPARATOR
Intervention: SWL (n=29)
Number of subjects: 202
Study 32935564 — intervention group
Group type: COMPARATOR
Intervention: URS (n=43)
Number of subjects: 202
Study 32935564 — intervention group
Group type: COMPARATOR
Intervention: URS + 4.8F DJS (n=39)
Number of subjects: 202
Study 32935564 — intervention group
Group type: COMPARATOR
Intervention: URS + 6F DJS (n=42)
Number of subjects: 202
Study 32935564 — intervention group
Group type: COMPARATOR
Intervention: Control (n=30)
Number of subjects: 202
Study 32503654 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan + ketogenic diet
Number of subjects: 518
Study 32503654 — intervention group
Group type: COMPARATOR
Intervention: irinotecan + normal diet
Number of subjects: 518
Study 35987538 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-app use group (iApp; n=25), using the mobile application for 4 min a day for 12 days (T0-T1)
Number of subjects: 55
Study 35987538 — intervention group
Group type: COMPARATOR
Intervention: Delayed-app group (dApp; n=20), starting the mobile application at T1 and using it for 12 consecutive days (T1-T2)
Number of subjects: 55
Study 34186232 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET) and personalized psychological intervention
Number of subjects: 111
Study 34186232 — intervention group
Group type: COMPARATOR
Intervention: Personalized psychological intervention (Control)
Number of subjects: 111
Study 34265388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of PBSCs plus HA after arthroscopic subchondral drilling
Number of subjects: 69
Study 34265388 — intervention group
Group type: COMPARATOR
Intervention: HA plus physiotherapy
Number of subjects: 69
Study 36282771 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ziprasidone (20-80 mg twice a day) for up to 26 weeks
Number of subjects: 23
Study 33661822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-based stigma at baseline
Number of subjects: 233
Study 33661822 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress at 4 months
Number of subjects: 233
Study 33661822 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor social support at 4 months
Number of subjects: 233
Study 35063224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) initiated within 8-33 hours (average 23 hours) of hospital admission.
Number of subjects: 10
Study 32814506 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU (1.2 g·min‐1 dextrose alone)
Number of subjects: 8
Study 32814506 — intervention group
Group type: COMPARATOR
Intervention: GLU+CAL (1.2 g·min‐1 dextrose with 2000 mg calcium)
Number of subjects: 8
Study 32814506 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU
Number of subjects: 8
Study 32814506 — intervention group
Group type: COMPARATOR
Intervention: GLU+CAL
Number of subjects: 8
Study 35502897 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscarinic acetylcholine receptor antagonist biperiden
Number of subjects: 81
Study 35502897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/D3 receptor antagonist amisulpride
Number of subjects: 81
Study 35502897 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (elevates acetylcholine levels)
Number of subjects: 81
Study 35502897 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (elevates dopamine levels)
Number of subjects: 81
Study 33499830 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-led educational intervention conducted by medical students
Number of subjects: 0
Study 33499830 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 0
Study 35255811 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g/d probiotic yogurt containing 106 cfu/g of Lactobacillus acidophilus and Bifidobacterium lactis strains
Number of subjects: 68
Study 35255811 — intervention group
Group type: COMPARATOR
Intervention: 300 g/d plain yogurt
Number of subjects: 68
Study 35255811 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 68
Study 33416608 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) hemoglobin A1c testing
Number of subjects: 1771
Study 616655105 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil/propofol
Number of subjects: 60
Study 616655105 — intervention group
Group type: COMPARATOR
Intervention: Propofol/isoflurane
Number of subjects: 60
Study 35100594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg d‐1 + diclofenac Na 100 mg tab (to be taken only during colic episodes)
Number of subjects: 90
Study 35100594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCL 0.4 mg cap + diclofenac Na 100 mg tab (to be taken only during colic episodes)
Number of subjects: 90
Study 35100594 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Na 100 mg tab only (to be taken only during colic episodes)
Number of subjects: 90
Study 33831805 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) + Cervical stabilization exercise (CSE)
Number of subjects: 0
Study 33831805 — intervention group
Group type: COMPARATOR
Intervention: Classical massage (CM) + Cervical stabilization exercise (CSE)
Number of subjects: 0
Study 35908546 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601 (combination of various herbal and non‐herbal components)
Number of subjects: 533
Study 35908546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 34626890 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure therapy (IVET) for 5 weeks
Number of subjects: 12
Study 34626890 — intervention group
Group type: COMPARATOR
Intervention: Sham physical activity (PA) monitoring for 5 weeks
Number of subjects: 12
Study 33587369 — intervention group
Group type: EXPERIMENTAL
Intervention: HARK (Hyaluronic Acid Filler)
Number of subjects: 0
Study 33587369 — intervention group
Group type: COMPARATOR
Intervention: Control (HAJV)
Number of subjects: 0
Study 33587369 — intervention group
Group type: EXPERIMENTAL
Intervention: HARK
Number of subjects: 0
Study 36054131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy milk (DM) - consumed twice daily (30g protein/day)
Number of subjects: 32
Study 36054131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and dairy milk (EX+DM) - 12 weeks whole-body PRT program (x3 sessions/week) and dairy milk (30g protein/day)
Number of subjects: 32
Study 36054131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (EX) - 12 weeks whole-body PRT program (x3 sessions/week)
Number of subjects: 32
Study 36054131 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - ad libitum dietary and exercise habits
Number of subjects: 32
Study 34903999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CoQ10 (200 mg) + ALA (250 mg) + ALCAR (250 mg) orally twice daily for two weeks
Number of subjects: 87
Study 34903999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 33569814 — intervention group
Group type: EXPERIMENTAL
Intervention: TASeFALL (email-based questionnaire)
Number of subjects: 40
Study 33569814 — intervention group
Group type: COMPARATOR
Intervention: Control (monthly paper-based questionnaire)
Number of subjects: 40
Study 33211921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement with calcium (200 mg daily), vitamin D3 (600 IU), and vitamin B6 (2 mg) for 12 months in group 1.
Number of subjects: 119
Study 33211921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement with calcium (200 mg daily), vitamin D3 (600 IU), and vitamin B6 (2 mg) for 12 months in group 2.
Number of subjects: 119
Study 33211921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplement) in group 3.
Number of subjects: 119
Study 35420668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 35420668 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32606059 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive balance training (RBT)
Number of subjects: 0
Study 32606059 — intervention group
Group type: COMPARATOR
Intervention: Aerobic and strength training (AST)
Number of subjects: 0
Study 35112166 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-100
Number of subjects: 0
Study 35112166 — intervention group
Group type: COMPARATOR
Intervention: AC
Number of subjects: 0
Study 35112166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 32752932 — intervention group
Group type: EXPERIMENTAL
Intervention: M207 3.8 mg
Number of subjects: 0
Study 32752932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35943913 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 75
Study 35943913 — intervention group
Group type: COMPARATOR
Intervention: Adhesive strips (AS)
Number of subjects: 75
Study 35902887 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab (6 mg/50 µL)
Number of subjects: 114
Study 35902887 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2 mg/50 µL)
Number of subjects: 114
Study 32321052 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PRGF
Number of subjects: 26
Study 32321052 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 26
Study 35842616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mum2BMoodBooster intervention
Number of subjects: 27
Study 33984247 — intervention group
Group type: EXPERIMENTAL
Intervention: No delay (0 hours)
Number of subjects: 24
Study 33984247 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour delay
Number of subjects: 24
Study 33984247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour delay
Number of subjects: 24
Study 32758299 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2 (arm A)
Number of subjects: 160
Study 32758299 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 (arm B)
Number of subjects: 160
Study 35238940 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 6609
Study 35238940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study 36239189 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic FMT (from healthy lean donor)
Number of subjects: 28
Study 36239189 — intervention group
Group type: COMPARATOR
Intervention: Autologous FMT (their own stool)
Number of subjects: 28
Study 33602399 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+PWI using cryoballoon
Number of subjects: 110
Study 33602399 — intervention group
Group type: COMPARATOR
Intervention: PVI using cryoballoon
Number of subjects: 110
Study 32879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum Midkine (MDK)
Number of subjects: 499
Study 35867857 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (n=39) with additional interventions: local anesthetic infiltration, IV dexmedetomidine, IV ketamine, additional IV dexamethasone, and repeated adductor canal block injections
Number of subjects: 78
Study 35867857 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=39) with standard multimodal analgesic regimen
Number of subjects: 78
Study 35867857 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (n=39)
Number of subjects: 78
Study 35867857 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=39)
Number of subjects: 78
Study 34352145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball abutment (Group B)
Number of subjects: 12